HIMS Hims & Hers Health, Inc.
Services-Offices & Clinics of Doctors of Medicine · NYSE · SEC CIK 1773751 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY29.8%
TTM net income YoY-242.6%
TTM EPS YoY-256.6%
Revenue 3-yr CAGR53.6%
Net income 3-yr CAGR—
Margins
Gross margin63.8%
Operating margin-8.1%
Net margin-6.7%
FCF margin0.3%
EBITDA margin-4.3%
Returns
ROE-40.8%
ROA-6.6%
ROIC (approx.)—
Asset turnover0.99x
Leverage & solvency
Liabilities / assets90.0%
Debt / equity0.00x
Current ratio0.92x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.94x
Accruals ratio-12.8%
Payout ratio—
Capex / revenue6.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $2.35B | $1.48B | $872.00M | $526.92M | $271.88M |
| Cost of revenue | $614.26M | $303.38M | $157.05M | $118.19M | $67.38M |
| Gross profit | $1.73B | $1.17B | $714.95M | $408.72M | $204.49M |
| SG&A expense | $272.72M | $167.77M | $129.88M | $98.19M | $113.66M |
| Operating income | $105.61M | $61.90M | -$29.45M | -$68.70M | -$115.04M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | $123.92M | $71.71M | -$21.57M | -$65.71M | -$110.80M |
| Income tax | -$4.44M | -$54.33M | $1.98M | -$31,000 | -$3.14M |
| Net income | $128.37M | $126.04M | -$23.55M | -$65.68M | -$107.66M |
| EBITDA | $160.12M | $78.99M | -$19.94M | -$61.22M | -$110.97M |
| EPS (basic) | 0.57 | 0.58 | -0.11 | -0.32 | -0.58 |
| EPS (diluted) | 0.51 | 0.53 | -0.11 | -0.32 | -0.58 |
| Weighted avg. shares (diluted) | 258.23M | 236.81M | 209.34M | 204.52M | 186.78M |
| Balance sheet | |||||
| Cash & equivalents | $228.62M | $221.44M | $96.66M | $47.63M | $72.64M |
| Short-term investments | $348.88M | $79.67M | $124.32M | $132.85M | $175.49M |
| Receivables | $32.15M | $6.10M | $6.70M | $3.90M | $4.10M |
| Inventory | $80.13M | $64.43M | $22.46M | $21.56M | $13.56M |
| Current assets | $767.64M | $395.83M | $265.05M | $216.59M | $269.90M |
| PP&E, net | — | — | — | $3.00M | $2.20M |
| Goodwill | $278.32M | $112.73M | $110.88M | $110.88M | $110.88M |
| Intangibles | $196.12M | $43.41M | $18.57M | $21.84M | $25.89M |
| Total assets | $2.15B | $707.54M | $441.19M | $366.34M | $420.58M |
| Current liabilities | $404.43M | $221.37M | $88.47M | $47.94M | $79.22M |
| Total liabilities | $1.61B | $230.82M | $97.16M | $54.60M | $85.97M |
| Shareholders' equity | $540.93M | $476.72M | $344.03M | $311.74M | $334.62M |
| Cash flow statement | |||||
| Operating cash flow | $300.01M | $251.08M | $73.48M | -$26.53M | -$34.41M |
| Capital expenditure | $242.60M | $52.80M | $26.50M | $7.20M | — |
| Free cash flow | $57.41M | $198.28M | $46.98M | -$33.73M | — |
| Investing cash flow | -$1.02B | -$19.05M | -$12.11M | $34.70M | -$156.27M |
| Financing cash flow | $729.62M | -$107.84M | -$11.47M | -$33.13M | $235.04M |
| Depreciation & amortization | $54.50M | $17.09M | $9.52M | $7.47M | $4.08M |
| Stock-based compensation | $135.24M | $92.32M | $66.08M | $42.82M | $67.21M |
| Share buybacks | $89.96M | $83.04M | $2.00M | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.